Navigation Links
Reportlinker Adds Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020
Date:10/14/2010

NEW YORK, Oct. 14 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020

http://www.reportlinker.com/p0312708/Colorectal-Cancer---Brazil-China-India-and-Russia-BRIC-Drug-Drug-Forecasts-and-Treatment-Analysis-to-2020.html

Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020

SummaryGlobalData, the industry analysis specialist, has released its new report, "Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020". The report is an essential source of information and analysis on the colorectal cancer therapeutics market in emerging countries, Brazil, China, India and Russia (BRIC). The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the colorectal cancer therapeutics market in Brazil, Russia, India and China. It analyses the treatment usage patterns in colorectal cancer therapeutics marketing BRIC countries. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the BRIC colorectal cancer therapeutics market, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

ScopeThe Scope of the report includes:

- An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized colorectal cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns data for Brazil, Russia, India and China from 2001 to 2009, forecast for 11 years to 2020.

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

Competitor assessment.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals and LCM activities.

- Analysis of unmet need in the market and target product profile including opportunity for target product.

- Technology trends analytic framework to assess strength of pipeline.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.

- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements and marketing rights.

- Analysis of the current and future market competition in the global colorectal cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.

- Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

Reasons to buyThe report will enhance your decision making capability. It will allow you to:

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the Japanese colorectal cancer therapeutics market.

- Understanding treatment preferences of physicians in disease state and across treatment flow.

- Accessing market sizing, forecasts and quantified growth opportunities in the Japanese colorectal cancer therapeutics market till 2020.

- Quantifying patient population in Japan to better design product pricing & launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- Performing benchmarking analysis and growth opportunities against currently marketed products

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.

- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

1 Colorectal Cancer: Executive Summary

1.1 The Colorectal Cancer Therapeutics Market in Bric Countries Is Gradually Growing Due To The Growth In Patient Volume As Well As Increased Adoption Of Branded Drugs

1.2 The Current Competition in the Colorectal Cancer Therapeutics Market is Weak as None of the Drugs Completely Addressed the Unmet Needs

1.3 The Colorectal Cancer Pipeline is Strong with Many Novel First-in-class Molecules in Late-stage Clinical Development

1.4 Unmet Needs Exist in the Colorectal Cancer Therapeutics Market in terms of Efficacy and Safety

2 Disease Overview

2.1 Overview

2.2 Epidemiology

2.3 Etiology

2.4 Symptoms

2.4.1 Colon Cancer

2.4.2 Rectal Cancer

2.5 Diagnosis

2.5.1 FOBT

2.5.2 Endoscopy

2.5.3 Optical Colonoscopy

2.5.4 Virtual Colonoscopy

2.5.5 Double Contrast Barium Enema (DCBE)

2.6 Pathology

2.6.1 Grading

2.7 Treatment

2.7.1 Colon Cancer Treatment by Stage

2.7.2 Rectal Cancer Treatment by Stage

2.7.3 Chemotherapy Options

2.8 Treatment Guidelines

3 Market Characterization

3.1 BRIC (Brazil, Russia, India and China)

3.1.1 Market Size

3.1.2 Forecasts

3.2 Brazil

3.2.1 Market Size

3.2.2 Drivers and Restraints

3.2.3 Impact on the Market

3.2.4 Forecasts

3.2.5 Future Impact

3.3 India

3.3.1 Market Size

3.3.2 Drivers and Restraints

3.3.3 Impact on the Market

3.3.4 Forecasts

3.3.5 Future Impact

3.4 China

3.4.1 Market Size

3.4.2 Drivers and Restraints

3.4.3 Impact on the Market

3.4.4 Forecasts

3.4.5 Future Impact

3.5 Russia

3.5.1 Market Size

3.5.2 Drivers and Restraints

3.5.3 Impact on the Market

3.5.4 Forecasts

3.5.5 Future Impact

3.6 Key Takeaway

4 Competitor Assessment

4.1 Strategic Competitor Assessment

4.1.1 Overview

4.1.2 Benchmarking

4.1.3 Current Competitor Assessment

4.2 Product Profiles

4.2.1 Avastin (bevacizumab)

4.2.2 Erbitux (cetuximab)

4.2.3 Xeloda (capecitabine)

4.2.4 Vectibix (panitumumab)

4.2.5 Eloxatin (oxaliplatin)

4.2.6 Camptosar (irinotecan)

4.2.7 Fluorouracil (5-FU)

4.2.8 Leucovorin (folinic acid)

4.3 Key Takeaway

5 Pipeline Assessment

5.1 Overview

5.2 Pipeline Analysis by Phase of Development

5.3 Pipeline by Mechanism of Action

5.4 Strategic Pipeline Assessment

5.4.1 Technology Trends Analytical Framework

5.5 Trends in Colorectal Cancer Pipeline

5.5.1 Increase in the Number of Vaccines in R&D Targeted at Stage III Colorectal Cancer

5.5.2 Novel First-in-Class Molecules in Late-stage Clinical Development Strengthening the Pipeline

5.5.3 Failure of key Molecules in Phase II and Phase III Development

5.6 Partners in Development

5.6.1 Licensing Agreements by Phase of Development

5.6.2 Licensing Agreements by Geography

5.6.3 Licensing Agreements: Colorectal Cancer Screening / Diagnostic Technology

5.7 Most Promising Drugs' Profiles

5.7.1 Aflibercept

5.7.2 Brivanib

5.7.3 OncoVAX

5.7.4 TroVax

5.7.5 KRX-0401 (Perifosine)

5.8 Colorectal Cancer Pipeline – Preclinical Phase

5.9 Colorectal Cancer Pipeline – Phase I

5.10 Colorectal Cancer Pipeline – Phase II

5.11 Colorectal Cancer Pipeline – Phase III

5.12 Key Takeaway

5.13 Unmet Need

5.14 Opportunity for Target Product

5.15 Target Product Profile

5.15.1 Ideal Characteristics

5.15.2 Target Product Description

5.16 Key Takeaway

6 Strategic Assessment

6.1 Key Events Impacting the Future Market

6.2 Market Impact Analysis

6.3 Future Market Scenario

6.4 Key Takeaway

7 Company Profiles

7.1 F. Hoffmann La Roche

7.1.1 Business Description

7.1.2 Financial Overview

7.1.3 SWOT Analysis

7.2 Bristol-Myers Squibb

7.2.1 Business Description

7.2.2 Financial Overview

7.2.3 SWOT Analysis

7.3 Sanofi-Aventis

7.3.1 Business Description

7.3.2 Financial Overview

7.3.3 SWOT Analysis

7.4 Debiopharm Group

7.4.1 Business Description

7.5 Merck KGaA

7.5.1 Business Description

7.5.2 Financial Overview

7.5.3 SWOT Analysis

7.6 Regeneron

7.6.1 Business Description

7.6.2 Financial Overview

7.6.3 SWOT Analysis

7.7 Vaccinogen BD

7.7.1 Overview

7.7.2 SWOT Analysis

7.8 Oxford BioMedica

7.8.1 Business Description

7.8.2 Financial Overview

7.8.3 SWOT Analysis

7.9 Auron Healthcare GmbH

7.9.1 Company Overview

7.10 AEterna Zentaris

7.10.1 Business Description

7.10.2 Financial Overview

7.10.3 SWOT Analysis

7.11 Keryx

7.11.1 Business Description

7.11.2 Financial Overview

7.11.3 SWOT Analysis

7.12 Abbott Laboratories

7.12.1 Business Description

7.12.2 Financial Performance

7.12.3 SWOT Analysis

7.13 Pfizer

7.13.1 Business Description

7.13.2 Financial Overview

7.13.3 SWOT Analysis

7.14 Light Sciences Oncology, Inc

7.14.1 Business Description

7.14.2 Financial Overview

7.14.3 SWOT Analysis

8 Deals Analysis

8.1 Key Highlights

8.2 Key Deals' Analysis

8.2.1 Eli Lilly Acquires ImClone

8.2.2 Astellas Pharma Acquires OSI Pharmaceuticals

8.2.3 Takeda Acquires IDM Pharma

8.2.4 Alchemia Acquires Meditech

8.2.5 Sanofi-Aventis Acquired Additional 15% Stake in Regeneron

8.2.6 BBM Holdings to Acquire YM Biosciences

8.2.7 Pfizer Acquires Assets of Campto from Sanofi-Aventis

8.2.8 Peptech Acquires cancer Antibodies from Scancell

8.2.9 Quest Pharma Tech Inc. Acquired Late Stage Immunotherapy Product Pipeline of Paladin Labs

8.2.10 Spectrum Pharmaceuticals Inc Acquired Oncology Drug Assets from Targent Inc

8.3 Deals Analysis by Geography

8.4 Deals Analysis by Deal Size

9 Appendix

9.1 Market Definitions

9.2 Abbreviations

9.3 Research Methodology

9.3.1 Coverage

9.3.2 Secondary Research

9.3.3 Forecasting

Analogous Forecasting Methodology

Diseased Population

Treatment Seeking Population

Diagnosis Population

Prescription Population

Forecasting Model for Therapeutic Areas

9.3.4 Primary Research

9.3.5 Expert Panel validation

9.3.6 Contact Us

9.3.7 Disclaimer

9.3.8 SourcesTable 1: Colorectal Cancer Therapeutics Market, Global, Staging of Colorectal Cancer, 2010

Table 2: Colorectal Cancer Therapeutics Market, Global, WHO Classification of Colorectal Carcinomas, 2010

Table 3: Colorectal Cancer Therapeutics Market, BRIC, Sales Value ($bn), 2001–2009

Table 4: Colorectal Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2001–2009

Table 5: Colorectal Cancer Therapeutics Market, BRIC, Patient Volume, 2001–2009

Table 6: Colorectal Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2001–2009

Table 7: Colorectal Cancer Therapeutics Market, BRIC, Sales Value ($bn), 2009–2020

Table 8: Colorectal Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2009–2020

Table 9: Colorectal Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 2009–2020

Table 10: Colorectal Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2009–2020

Table 11: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001–2009

Table 12: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001–2009

Table 13: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 2001–2009

Table 14: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2001–2009

Table 15: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009–2020

Table 16: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009–2020

Table 17: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 2009–2020

Table 18: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2009–2020

Table 19: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 2001–2009

Table 20: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2001–2009

Table 21: Colorectal Cancer Therapeutics Market, India, Patient Volume, 2001–2009

Table 22: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 2001–2009

Table 23: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 2009–2020

Table 24: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2009–2020

Table 25: Colorectal Cancer Therapeutics Market, India, Patient Volume, 2009–2020

Table 26: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 2009–2020

Table 27: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 2001–2009

Table 28: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2001–2009

Table 29: Colorectal Cancer Therapeutics Market, China, Patient Volume, 2001–2009

Table 30: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 2001–2009

Table 31: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 2009–2020

Table 32: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2009–2020

Table 33: Colorectal Cancer Therapeutics Market, China, Patient Volume, 2009–2020

Table 34: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 2009–2020

Table 35: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 2001–2009

Table 36: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2001–2009

Table 37: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 2001–2009

Table 38: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2001–2009

Table 39: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 2009–2020

Table 40: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2009–2020

Table 41: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 2009–2020

Table 42: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2009–2020

Table 43: Colorectal Cancer, Global, Safety Profile of Standard Treatment, 2010

Table 44: Colorectal Cancer Therapeutics Market, Global, Benchmarking Major Marketed Products, 2010

Table 45: Colorectal Cancer, Global, Avastin Adverse Effects Incidence, 2010

Table 46: Colorectal Cancer Therapeutics Market, Global, Erbitux, Incidence of Adverse Effects, 2010

Table 47: Colorectal Cancer Therapeutics Market, Global, Xeloda, Adverse Effects Incidence, 2010

Table 48: Colorectal Cancer Therapeutics Market, Global, Vectibix, PRECEPT Interim Results, 2010

Table 49: Colorectal Cancer Therapeutics Market, Global, Vectibix, Incidence of Adverse Events, 2010

Table 50: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Efficacy, 2010

Table 51: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Incidence of Adverse Events, 2010

Table 52: Colorectal Cancer Therapeutics Market, Global, Technology Licensing Agreements Description, 2010

Table 53: Colorectal Cancer Therapeutics Market, Global, Preclinical Phase Pipeline, July 2010

Table 54: Colorectal Cancer, Global, Phase I Pipeline, July 2010

Table 55: Colorectal Cancer, Global, Phase II Pipeline, July 2010

Table 56: Colorectal Cancer, Global, Phase III Pipeline, July 2010

Table 57: Colorectal Cancer Therapeutics Market, Global, Commonly Prescribed Treatment Options, 2010

Table 58: Colorectal Cancer Therapeutics Market, Global, Characteristics of Ideal Drug Which Satisfies the Unmet Needs, 2010

Table 59: Colorectal Cancer Therapeutics Market, Global, Description of Ideal Drug Which Satisfies the Unmet Needs, 2010

Figure 1: Colorectal Cancer Therapeutics Market, BRIC, Sales Value ($m), 2001-2020

Figure 2: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010

Figure 3: Colorectal Cancer Therapeutics Market, BRIC, Opportunity and Unmet Need, 2009

Figure 4: Colorectal Cancer, Global, Colon Cancer Treatment Guidelines, 2010

Figure 5: Colorectal Cancer, Global, Rectal Cancer Treatment Guidelines, 2010

Figure 6: Colorectal Cancer Therapeutics Market, BRIC, Sales Value ($bn), 2001–2009

Figure 7: Colorectal Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2001–2009

Figure 8: Colorectal Cancer Therapeutics Market, BRIC, Patient Volume, 2001–2009

Figure 9: Colorectal Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2001–2009

Figure 10: Colorectal Cancer Therapeutics Market, BRIC, Sales Value ($bn), 2009–2020

Figure 11: Colorectal Cancer Therapeutics Market, BRIC, Annual Cost of Therapy ($), 2009–2020

Figure 12: Colorectal Cancer Therapeutics Market, BRIC, Patient Volume (absolute), 2009–2020

Figure 13: Colorectal Cancer Therapeutics Market, BRIC, Treatment Usage Patterns, 2009–2020

Figure 14: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 2001–2009

Figure 15: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2001–2009

Figure 16: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 2001–2009

Figure 17: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2001–2009

Figure 18: Colorectal Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2009

Figure 19: Colorectal Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2010

Figure 20: Colorectal Cancer Therapeutics Market, Brazil, Sales Value ($m), 2009–2020

Figure 21: Colorectal Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2009–2020

Figure 22: Colorectal Cancer Therapeutics Market, Brazil, Patient Volume, 2009–2020

Figure 23: Colorectal Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2009–2020

Figure 24: Colorectal Cancer Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2009–2020

Figure 25: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 2001–2009

Figure 26: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2001–2009

Figure 27: Colorectal Cancer Therapeutics Market, India, Patient Volume, 2001–2009

Figure 28: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 2001–2009

Figure 29: Colorectal Cancer Therapeutics Market, India, Market Drivers and Restraints, 2009

Figure 30: Colorectal Cancer Therapeutics Market, India, The Impact of Historical Events on the Market, 2010

Figure 31: Colorectal Cancer Therapeutics Market, India, Sales Value ($m), 2009–2020

Figure 32: Colorectal Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2009–2020

Figure 33: Colorectal Cancer Therapeutics Market, India, Patient Volume, 2009–2020

Figure 34: Colorectal Cancer Therapeutics Market, India, Treatment Usage Patterns, 2009–2020

Figure 35: Colorectal Cancer Therapeutics Market, India, Future Market Drivers and Restraints, 2009–2020

Figure 36: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 2001–2009

Figure 37: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2001–2009

Figure 38: Colorectal Cancer Therapeutics Market, China, Patient Volume, 2001–2009

Figure 39: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 2001–2009

Figure 40: Colorectal Cancer Therapeutics Market, China, Market Drivers and Restraints, 2010

Figure 41: Colorectal Cancer Therapeutics Market, China, The Impact of Historical Events on the Market, 2010

Figure 42: Colorectal Cancer Therapeutics Market, China, Sales Value ($m), 2009–2020

Figure 43: Colorectal Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2009–2020

Figure 44: Colorectal Cancer Therapeutics Market, China, Patient Volume, 2009–2020

Figure 45: Colorectal Cancer Therapeutics Market, China, Treatment Usage Patterns, 2009–2020

Figure 46: Colorectal Cancer Therapeutics Market, China, Future Market Drivers and Restraints, 2009–2020

Figure 47: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 2001–2009

Figure 48: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2001–2009

Figure 49: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 2001–2009

Figure 50: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2001–2009

Figure 51: Colorectal Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2009

Figure 52: Colorectal Cancer Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2010

Figure 53: Colorectal Cancer Therapeutics Market, Russia, Sales Value ($m), 2009–2020

Figure 54: Colorectal Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2009–2020

Figure 55: Colorectal Cancer Therapeutics Market, Russia, Patient Volume, 2009–2020

Figure 56: Colorectal Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2009–2020

Figure 57: Colorectal Cancer Therapeutics Market, Russia, Future Market Drivers and Restraints, 2009–2020

Figure 58: Colorectal Cancer Therapeutics Market, Global, Clinical Endpoints for Benchmarking, 2010

Figure 59: Colorectal Cancer Therapeutics Market, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2010

Figure 60: Colorectal Cancer Therapeutics Market, Global, Avastin, Life Cycle Management Activities, 2004–2010

Figure 61: Colorectal Cancer Therapeutics Market, Global, Erbitux, Life Cycle Management Activities, 2004–2010

Figure 62: Colorectal Cancer Therapeutics Market, Global, Xeloda, Chemical Structure, 2010

Figure 63: Colorectal Cancer Therapeutics Market, Global, Xeloda, Life Cycle Management Activities, 2010

Figure 64: Colorectal Cancer Therapeutics Market, Global, Vectibix, Life Cycle Management Activities, 2010

Figure 65: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Chemical Structure, 2010

Figure 66: Colorectal Cancer Therapeutics Market, Global, Eloxatin, Life Cycle Management Activities, 2010

Figure 67: Colorectal Cancer Therapeutics Market, Global, Camptosar, Chemical Structure

Figure 68: Colorectal Cancer Therapeutics Market, Global, Camptosar, Life Cycle Management Activities, 2010

Figure 69: Colorectal Cancer Therapeutics Market, Global, Fluorouracil, Chemical Structure

Figure 70: Colorectal Cancer Therapeutics Market, Global, Leucovorin, Chemical Structure

Figure 71: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Therapy (%), 2010

Figure 72: Colorectal Cancer Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2010

Figure 73: Colorectal Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action, 2010

Figure 74: Colorectal Cancer Therapeutics Market, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2010

Figure 75: Colorectal Cancer Therapeutics Market, Global, Technology Trends Description of Pipeline Drugs, 2010

Figure 76: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Phase of Development (%), 2004-2010

Figure 77: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Geography (%), 2010

Figure 78: Colorectal Cancer Therapeutics Market, Global, Licensing Agreements by Screening/Diagnostic Technology (%), 2010

Figure 79: Colorectal Cancer Therapeutics Market, Global, Brivanib Chemical Structure, 2010

Figure 80: Colorectal Cancer Therapeutics Market, Global, Perifosine Chemical Structure, 2010

Figure 81: Colorectal Cancer Therapeutics Market, Global, Median Overall Survival for Metastatic Colorectal Cancer Patients (months), 2010

Figure 82: Colorectal Cancer Therapeutics Market, Global, Opportunity and Unmet Need, 2010

Figure 83: Colorectal Cancer Therapeutics Market, Unmet Need by Geography, 2010

Figure 84: Colorectal Cancer, Global, Key Events Impacting the Future Market

Figure 85: Colorectal Cancer Therapeutics Market, Global, Implications for Future Market Competition, 2010

Figure 86: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography, 2010

Figure 87: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Geography (%), 2010

Figure 88: Colorectal Cancer Therapeutics Market, Global, Merger and Acquisition Deals by Deal Size (%), 2010

Figure 89: GlobalData Market Forecasting Model

To order this report:Drug and Medication Industry: Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its fiscal year ... --> --> GAAP results: Revenue for ... $5.1 million or 4.1% from the third quarter of ... fourth quarter of 2014. Revenue for the year ended ...
(Date:2/4/2016)... 2016  Aethlon Medical, Inc. (Nasdaq: AEMD ... to treat life-threatening diseases, today announced results for ... 31, 2015. --> ... in our last quarterly call, we strategically advanced ... objective to establish the Aethlon Hemopurifier® as a ...
(Date:2/4/2016)... 4, 2016  AMRI (NASDAQ:  AMRI) today announced that ... and President of Pfizer Global Supply, has been elected to ... 2016. In addition, the Company announced that Mr. Gabe ... since 2010, has retired from the AMRI Board of Directors ... other business ventures.  William S. Marth , ...
Breaking Medicine Technology:
(Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , ... the world with an estimated 5000 perioperative nurses in attendance to study ...
(Date:2/6/2016)... ... ... With the FCPX LUT: Summer pack from Pixel Film Studios, ... is a Lookup Table that contains a mathematical formula for modifying an image. The ... manipulating each pixel, LUT's can change each color range differently, it gives the user ...
(Date:2/6/2016)... , ... February 06, 2016 , ... ... of eating disorder treatment helps to reduce the frequency and level of relapse. ... Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air ... variety of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, ... , For Valentine’s Day, not only are long-stem roses available, but also other ...
Breaking Medicine News(10 mins):